Abstract
Investigators in this study explored levels of soluble CD27 (sCD27), interleukin (IL)-8, and IL-10 in B-cell chronic lymphocytic leukemia (B-CLL), and the correlation of these levels with disease stage and prognosis. Plasma IL-8, IL-10, and sCD27 levels were assessed with enzyme-linked immunosorbent assay tests in 22 healthy donors and 70 patients with B-CLL (49 men and 21 women). Mean patient age was 61.57 y (range, 44–75 y). Mean healthy donor age was 62.09 y (range, 40–72 y). In the study group, mean values were as follows: plasma IL-8, 284.758 pg/mL (0–1000 pg/mL); plasma IL-10, 26.152 pg/mL (0–100 pg/mL); sCD27, 731.357 U/mL (139.9–1000 U/mL); white blood cell count, 59.9 × 109/L (0.8–250.0 × 109/L); hemoglobin count, 11.2 g/dL (5.0–16.2 g/dL); platelet count, 162.5 × 109/L (29.8–317 × 109/L); B2 microglobulin (B2M) 3350.2 mg/L (274.7–7499.9 mg/L); CD38, 19.5%; and lactate dehydrogenase (count, 497.5 U/L (263.0–1507 U/L). Patients represented all Rai stages, with 22.9% at stage 0, 11.4% at stage I, 11.4% at stage II, 41.4% at stage III, and 12.9% at stage IV. Plasma levels of IL-8, IL-10, and sCD27 were correlated between study and control groups; significantly higher IL-8 (P=.001) and sCD27 (P=.000) levels were found, but the IL-10 level was not significant (P=.139). Plasma IL-10 (P=.01) and sCD27 (P=.008) were positively correlated with Rai stage, but IL-8 was not (P=.146). Levels of sCD27 were significantly correlated with values for B2M (P=.000), hemoglobin (P=.028), lactate dehydrogenase (P=.001), CD19 (P=.03), and IL-10 (P=.000). IL-8 was significantly correlated with white blood cell (P=.000) count, and CD38 (P=.001) and CD5 (P=.006) levels. IL-10 was significantly correlated with B2M (P=.017), CD19 (P=.000), platelet (P=.002), and CD27 (P=.000). In survival distributions for CD27, IL-8 and IL-10 were found to have more significant relationships for all parameters (P=.0000). In conclusion, the authors suggest that sCD27, IL-8, and IL-10 are more significant prognostic factors for B-CLL when compared with others, and these values should correlate with new prognostic factors (eg, zeta-associated protein-70, mutated/unmutated immunoglobulin variable heavy chain).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kipps T. Chronic lymphocytic leukemia and related disorders. In: Beutler E, Lichtman M, Coller B, Kipps T, Seligsohn U, eds.Williams Hematology, 6th ed. New York, NY: McGraw-Hill Health Professions Division; 2001:1163–1194.
Skinnider LF, Tan L, Schmidt J, Armitage G. Chronic lymphocytic leukemia: a review of 745 cases and assessment of clinical staging.Cancer. 1982;50:2951–2955.
Spati B, Child JA, Kerruish SM, Cooper EH. Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia: a multicentre study.Acta Haematol. 1980;64:79–86.
Molica S, Levato D, Cascavilla N, Levato L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia.Eur J Haematol. 1999;62:117–122.
Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia.Blood. 1996;88:4259–4264.
van Oers MH, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies.Blood. 1993;82:3430–3436.
Molica S, Vitelli G, Levato D, et al. CD27 in B-cell chronic lymphocytic leukemia: cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily.Haematologica. 1998;83:398–402.
Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients.Blood. 1987;69:929–936.
Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.Blood. 1997;89:2516–2522.
Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.Blood. 1998;91:4342–4349.
DamLe RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood. 1999;94:1840–1847.
Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia.Blood. 2001;98:2633–2639.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood. 1999;94: 1848–1854.
Montserrat E, Marques-Pereira JP, Gallart MT, Rozman C. Bone marrow histopathologic patterns and immunologic findings in B-cell chronic lymphocytic leukemia.Cancer. 1984;54:447–451.
Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.N Engl J Med. 2004;351:893–901.
Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family.Ann Rev Immunol. 1991;9:617–648.
di Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein.Blood. 1994;84:220–228.
di Celle PF, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.Blood. 1996;87:4382–4389.
Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by the Th1 clones.J Exp Med. 1989;170:2081–2095.
Go NF, Castle BE, Barrett R, et al. Interleukin-10 (IL-10), a new B-cell stimulatory factor: unresponsiveness of X-chromosome linked immunodeficiency B cells.J Exp Med. 1990;172: 1625–1631.
Rousset F, Garcia E, Defrance T, et al. IL-10 is a potent growth factor for activated human B lymphocytes.Proc Natl Acad Sci USA. 1992;898:1890–1893.
Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick D. Interleukin-10: a novel stimulator factor for mast cells and their progenitors.J Exp Med. 1991;173:507–510.
Blay J-Y, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor.Blood. 1993;82:2169–2174.
Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin’s lymphoma.Leuk Lymphoma. 1997; 28:251–259.
Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.Blood. 1995;85: 2516–2520.
Blay J-Y, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J. Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with human immunodeficiency virus-related diffuse large-cell non-Hodgkin’s lymphomas [letter].Blood. 1995;86:4702–4707.
Sarris AH, Kliche K-O, Pethambaran P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin’s disease and are associated with inferior failure-free survival.Ann Oncol. 1999;10:433–440.
Lotz M, Setareh M, von Kempis J, Schwarz H. The nerve growth factor/tumor necrosis factor receptor family.J Leuk Biol. 1996;60:1–7.
Gruss H-J, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.Blood. 1995;85:3378–3404.
Rui H, Kirken RA, Duhe RJ, Howard OMZ, Evans GA, Farrar WL. Lymphokine-induced signal transduction. In: Townley R, Agrawal DK, eds.Immunopharmacology of Allergic Disease. New York, NY: Marcel Dekker, Inc.; 1996:29–77.
Van Lier RAW, Pool MO, Kabel P, et al. Anti-CD27 monoclonal antibodies identify two functionally distinct subpopulations within the CD4+ T cell subset.Eur J Immunol. 1988;18:811–816.
Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C. CD27-CD70 interaction regulated B-cell activation by T-cells.Proc Natl Acad Sci USA. 1995;92:11249–11253.
Agematsu K, Kobata T, Feng-Chun Y, et al. CD27/CD70 interaction directly drives B cell IgG and IgM synthesis.Eur J Immunol. 1995;25:2825–2829.
Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig) M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells.J Exp Med. 1998;188:1679–1689.
Tangye SG, Liu Y-J, Aversa G, Phillips JH, deVries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27.J Exp Med. 1998;188:1691–1703.
Reed JC. Molecular biology of chronic lymphocytic leukemia.Semin Oncol. 1998;25:11–18.
Egle A, Marschitz I, Posch B, Herold M, Greil R. IL-10 serum levels in B-cell chronic lymphocytic leukemia.Br J Haematol. 1996;94:211–212.
Jurlander J, Lai CF, Tan J, et al. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells.Blood. 1997;89:4146–4152.
Sjoberg J, Aguilar-Santelises M, Sjogren AM, et al. Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukemia inversely correlates with progression of disease.Br J Haematol. 1996;92:393–400.
Kamper EF, Papaphilis AD, Angelopoulou MK, et al. Serum levels of tetranectin, intracellular adhesion molecule-1 and interleukin-10 in B-cell chronic lymphocytic leukemia.Clin Biochem. 1999;32:639–645.
Knauf WU, Ehlers B, Bisson S, Thiel E. Serum levels of interleukin-10 in B-cell chronic lymphocytic leukemia.Blood. 1995;86:4382–4383.
Lee BN, Estrov Z, Huh Y, et al. Peripheral blood normal polyclonal B cells from patients with B-CLL produce B-cell stimulatory cytokines [abstract 2758].Proc Am Assoc Cancer Res. 1998;36.
Tangye SG, Weston KM, Raison RL. Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD51 B-cells.Leuk Lymphoma. 1998;31:121–130.
Kitabayashi A, Kirokawa M, Miura AB. The role of interleukin-10 (IL-10) in chronic B-cell lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death.Int J Hematol. 1995;62:99–106.
Fluckiger AC, Duran I, Banchereau J. Interleukin-10 induces apoptotic cell death of B-cell chronic lymphocytic leukemia cells.J Exp Med. 1994;179:91–99.
Levy C, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein.J Clin Invest. 1994;93:424–428.
Baiocchi RA, Ross ME, Tan JC, et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10.Blood. 1995;85:1063–1074.
Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo.Br J Haematol. 1994;88:268–274.
Bushcle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.J Exp Med. 1993;177:213–218.
Castejon R, Vargas JA, Romero Y, Briz M, Munoz RM, Durantez A. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia.Cytometry. 1999;38:224–230.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kara, I.O., Sahin, B. & Gunesacar, R. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: Correlation with disease stage and prognosis. Adv Therapy 24, 29–40 (2007). https://doi.org/10.1007/BF02849990
Issue Date:
DOI: https://doi.org/10.1007/BF02849990